560 related articles for article (PubMed ID: 22549110)
1. Methodology validation, intra-subject reproducibility and stability of exhaled volatile organic compounds.
Basanta M; Ibrahim B; Douce D; Morris M; Woodcock A; Fowler SJ
J Breath Res; 2012 Jun; 6(2):026002. PubMed ID: 22549110
[TBL] [Abstract][Full Text] [Related]
2. Influences of mixed expiratory sampling parameters on exhaled volatile organic compound concentrations.
Thekedar B; Oeh U; Szymczak W; Hoeschen C; Paretzke HG
J Breath Res; 2011 Mar; 5(1):016001. PubMed ID: 21383425
[TBL] [Abstract][Full Text] [Related]
3. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma.
Fens N; Zwinderman AH; van der Schee MP; de Nijs SB; Dijkers E; Roldaan AC; Cheung D; Bel EH; Sterk PJ
Am J Respir Crit Care Med; 2009 Dec; 180(11):1076-82. PubMed ID: 19713445
[TBL] [Abstract][Full Text] [Related]
4. A profile of volatile organic compounds in breath discriminates COPD patients from controls.
Van Berkel JJ; Dallinga JW; Möller GM; Godschalk RW; Moonen EJ; Wouters EF; Van Schooten FJ
Respir Med; 2010 Apr; 104(4):557-63. PubMed ID: 19906520
[TBL] [Abstract][Full Text] [Related]
5. Analysis of volatile organic compounds in exhaled breath by gas chromatography-mass spectrometry combined with chemometric analysis.
Dallinga JW; Smolinska A; van Schooten FJ
Methods Mol Biol; 2014; 1198():251-63. PubMed ID: 25270934
[TBL] [Abstract][Full Text] [Related]
6. A dual center study to compare breath volatile organic compounds from smokers and non-smokers with and without COPD.
Gaida A; Holz O; Nell C; Schuchardt S; Lavae-Mokhtari B; Kruse L; Boas U; Langejuergen J; Allers M; Zimmermann S; Vogelmeier C; Koczulla AR; Hohlfeld JM
J Breath Res; 2016 Apr; 10(2):026006. PubMed ID: 27082437
[TBL] [Abstract][Full Text] [Related]
7. An adaptive breath sampler for use with human subjects with an impaired respiratory function.
Basanta M; Koimtzis T; Singh D; Wilson I; Thomas CL
Analyst; 2007 Feb; 132(2):153-63. PubMed ID: 17260076
[TBL] [Abstract][Full Text] [Related]
8. Experimental setup and analytical methods for the non-invasive determination of volatile organic compounds, formaldehyde and NOx in exhaled human breath.
Riess U; Tegtbur U; Fauck C; Fuhrmann F; Markewitz D; Salthammer T
Anal Chim Acta; 2010 Jun; 669(1-2):53-62. PubMed ID: 20510903
[TBL] [Abstract][Full Text] [Related]
9. Chronic intestinal Mycobacteria infection: discrimination via VOC analysis in exhaled breath and headspace of feces using differential ion mobility spectrometry.
Purkhart R; Köhler H; Liebler-Tenorio E; Meyer M; Becher G; Kikowatz A; Reinhold P
J Breath Res; 2011 Jun; 5(2):027103. PubMed ID: 21512209
[TBL] [Abstract][Full Text] [Related]
10. Novel extraction of volatile biomarkers from canine breath for gas chromatography-mass spectrometry.
Dissanayake S; Lathan P; Mlsna T
J Breath Res; 2012 Dec; 6(4):041001. PubMed ID: 22989995
[TBL] [Abstract][Full Text] [Related]
11. Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath.
Sarbach C; Stevens P; Whiting J; Puget P; Humbert M; Cohen-Kaminsky S; Postaire E
Ann Pharm Fr; 2013 Jul; 71(4):203-15. PubMed ID: 23835018
[TBL] [Abstract][Full Text] [Related]
12. Comparison of volatile organic compounds from lung cancer patients and healthy controls-challenges and limitations of an observational study.
Schallschmidt K; Becker R; Jung C; Bremser W; Walles T; Neudecker J; Leschber G; Frese S; Nehls I
J Breath Res; 2016 Oct; 10(4):046007. PubMed ID: 27732569
[TBL] [Abstract][Full Text] [Related]
13. Machine learning methods on exhaled volatile organic compounds for distinguishing COPD patients from healthy controls.
Phillips CO; Syed Y; Parthaláin NM; Zwiggelaar R; Claypole TC; Lewis KE
J Breath Res; 2012 Sep; 6(3):036003. PubMed ID: 22759349
[TBL] [Abstract][Full Text] [Related]
14. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD.
Dragonieri S; Annema JT; Schot R; van der Schee MP; Spanevello A; Carratú P; Resta O; Rabe KF; Sterk PJ
Lung Cancer; 2009 May; 64(2):166-70. PubMed ID: 18834643
[TBL] [Abstract][Full Text] [Related]
15. Ultrafast gas chromatography coupled to electronic nose to identify volatile biomarkers in exhaled breath from chronic obstructive pulmonary disease patients: A pilot study.
Rodríguez-Aguilar M; Ramírez-García S; Ilizaliturri-Hernández C; Gómez-Gómez A; Van-Brussel E; Díaz-Barriga F; Medellín-Garibay S; Flores-Ramírez R
Biomed Chromatogr; 2019 Dec; 33(12):e4684. PubMed ID: 31423612
[TBL] [Abstract][Full Text] [Related]
16. The versatile use of exhaled volatile organic compounds in human health and disease.
Boots AW; van Berkel JJ; Dallinga JW; Smolinska A; Wouters EF; van Schooten FJ
J Breath Res; 2012 Jun; 6(2):027108. PubMed ID: 22621865
[TBL] [Abstract][Full Text] [Related]
17. Screening for emphysema via exhaled volatile organic compounds.
Cristescu SM; Gietema HA; Blanchet L; Kruitwagen CL; Munnik P; van Klaveren RJ; Lammers JW; Buydens L; Harren FJ; Zanen P
J Breath Res; 2011 Dec; 5(4):046009. PubMed ID: 22071870
[TBL] [Abstract][Full Text] [Related]
18. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.
Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K
Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150
[TBL] [Abstract][Full Text] [Related]
19. Determination of volatile organic compounds as biomarkers of lung cancer by SPME-GC-TOF/MS and chemometrics.
Rudnicka J; Kowalkowski T; Ligor T; Buszewski B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(30):3360-6. PubMed ID: 21982505
[TBL] [Abstract][Full Text] [Related]
20. Breath profiles by electronic nose correlate with systemic markers but not ozone response.
Biller H; Holz O; Windt H; Koch W; Müller M; Jörres RA; Krug N; Hohlfeld JM
Respir Med; 2011 Sep; 105(9):1352-63. PubMed ID: 21439804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
